Charles Conway - 06 Jan 2022 Form 4 Insider Report for Biohaven Pharmaceutical Holding Co Ltd.

Role
Chief Scientific Officer
Signature
/s/ George Clark, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
06 Jan 2022
Net transactions value
-$222,948
Form type
4
Filing time
07 Jan 2022, 20:18:08 UTC
Previous filing
26 Nov 2021
Next filing
03 Oct 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BHVN Common Shares Options Exercise $0 +3,750 +19% $0.000000 23,935 06 Jan 2022 Direct F1
transaction BHVN Common Shares Tax liability $222,948 -1,800 -7.5% $123.86* 22,135 06 Jan 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BHVN Restricted Share Unit Award Options Exercise $0 -3,750 -33% $0.000000 7,500 06 Jan 2022 Common Shares 3,750 Direct F3, F4, F5
transaction BHVN Employee Stock Option (right to buy) Award $0 +23,000 $0.000000 23,000 07 Jan 2022 Common Shares 23,000 $128.87 Direct F6
transaction BHVN Restricted Share Unit Award Award $0 +11,500 $0.000000 11,500 07 Jan 2022 Common Shares 11,500 Direct F3, F5, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This balance includes 288 shares that were acquired through the Biohaven Employee Share Purchase Plan on May 31, 2021.
F2 No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units.
F3 Each restricted share unit represents the contingent right to receive one common share of the Issuer.
F4 The reporting person was granted 15,000 restricted share units on January 6, 2021, vesting in four equal installments on January 6, 2021, 2022, 2023 and 2024, subject to the reporting person's continued service with the Issuer at each vesting date.
F5 Not applicable.
F6 The shares underlying this option vest in four equal installments on January 7, 2022, 2023, 2024 and 2025, subject to the reporting person's continuous service with the Issuer at each vesting date.
F7 The reporting person was granted 11,500 restricted share units on January 7, 2022, vesting in four equal installments on January 7, 2022, 2023, 2024 and 2025, subject to the reporting person's continued service with the Issuer at each vesting date. 100% of these restricted share units are generally subject to settlement in 10 equal annual installments after separation from service.

Remarks:

Exhibit List: Exhibit 24: Power of attorney